How to Get GLP-1 Medications in 2026

The Four Pathways to GLP-1 Access

Most patients who successfully access GLP-1 medications do so through one of four distinct routes. Understanding which applies to your situation determines everything from which drug you can get to what it will cost.

Who Qualifies for GLP-1 Medications

FDA eligibility for chronic weight management GLP-1 prescribing is determined by current BMI and documented comorbidities—not historical weight, not failed diet attempts, and not whether a PCP has referred you. Understanding the thresholds precisely matters because many patients who qualify are not told so, and some who believe they qualify do not meet the labeled criteria.

Eligibility is assessed at current BMI. Patients who have already lost weight but remain above the thresholds still qualify. Prior weight loss efforts are not a disqualifier—they are actually clinically favorable, because behavioral engagement improves GLP-1 outcomes. For patients with type 2 diabetes, treatment goals differ meaningfully from obesity-only prescribing: the monitoring schedules, dose targets, drug interactions, and expected weight loss magnitude are all distinct.

Cost and Insurance Realities

The single most common reason patients do not access GLP-1 medications is cost. Brand-name Wegovy and Zepbound list at approximately $1,029–$1,349 per month without insurance—making them among the most expensive non-specialty medications available in the United States. Understanding the cost landscape requires distinguishing between four separate questions: whether your plan covers the drug, what you will actually pay if it does, what alternatives exist if it does not, and how to use pre-tax accounts to reduce any out-of-pocket burden.

Insurance coverage for obesity-indication GLP-1s remains narrow. Fewer than 30% of large employer plans covered Wegovy or Zepbound as of 2025 data. Medicare historically excluded obesity medications, though recent regulatory changes are expanding coverage for cardiovascular indications. Medicaid coverage exists in approximately 27 states. Where coverage does exist, prior authorization is required in essentially all cases—and initial denials are common but frequently overturned on appeal.

Telehealth and Access Pathways

Telehealth has fundamentally changed GLP-1 access. More than 50 licensed platforms now offer physician-supervised GLP-1 prescribing without requiring an existing primary care relationship, a referral, or an in-person visit. The clinical model varies considerably across programs—from genuine physician-supervised care with structured dose escalation and follow-up, to programs that function primarily as subscription services with minimal clinical oversight.

For patients who cannot access covered brand-name GLP-1s through traditional insurance channels, telehealth cash-pay programs provide a meaningful alternative—but the quality of clinical oversight varies significantly, and evaluating programs before enrolling requires looking beyond the marketing page.

Which GLP-1 Medication and Why

The question patients most often ask—“which medication is best?”—does not have a single answer. The choice between semaglutide and tirzepatide, between brand-name and compounded formulations, and between injectable and oral forms involves efficacy data, tolerability, access, cost, and individual clinical factors that require physician assessment. What the clinical evidence does allow is a precise description of what is known about each option and where the evidence is strongest.

Tirzepatide consistently produces greater mean weight loss than semaglutide in clinical trials. But population means mask substantial individual variation, and a patient who responds well to semaglutide may achieve outcomes superior to the tirzepatide population average. Access and cost considerations further complicate a purely efficacy-based comparison.

Safety, Side Effects, and Long-Term Use

GLP-1 medications have a well-characterized safety profile developed across more than a decade of clinical use in diabetes, and across more than four years of large-scale weight management trial data. The primary safety consideration in clinical practice is the gastrointestinal side effect burden during dose escalation—which is predictable, manageable with appropriate titration, and attenuates significantly over time. The more clinically underappreciated issues involve what happens to lean mass during rapid weight loss, what occurs when treatment is stopped, and how absolute contraindications function in practice.

Key Takeaways

GLP-1 medications represent a genuine clinical advance in obesity and metabolic medicine. They are not weight-loss supplements; they are prescription medications requiring physician evaluation, dose escalation management, and ongoing clinical oversight. The access pathway that applies to any individual patient depends on their clinical profile, insurance coverage, and the programs available in their state.

The evidence consistently supports tirzepatide producing greater weight loss than semaglutide, but cost, access, and individual response mean that semaglutide remains the appropriate first-line choice for many patients. Brand-name and compounded formulations involve different regulatory, quality, and cost considerations that a prescribing physician should discuss explicitly. And the biology of weight regain after discontinuation means that for most patients, these medications are best understood as long-term rather than finite treatments.